Responsible for treating thousands of hematology and oncology patients over the past 30 years, Kenneth D. Nahum, DO, works at Regional Cancer Care Associates, LLC, in Howell, New Jersey. Active in his professional community, Dr. Kenneth D. Nahum maintains membership with the American Society of Hematology (ASH).ASH’s medical journal, Blood, recently reported exciting news about the effort to develop a treatment for cold agglutinin disease, a rare blood disorder with no approved treatment at present. Affecting about 10,000 people in the United States and Europe, cold agglutinin is an immune system malfunction that mistakenly causes antibodies to target and destroy red blood cells faster than the bone marrow can replace them.As reported in Blood, the first clinical trial with 10 humans showed the investigational drug sutimlimab may be an effective treatment for cold agglutinin disease. Sutimlimab, which is a specific C1s inhibitor, showed the ability to prevent red blood cell destruction and increase hemoglobin levels in seven of the 10 patients. The patients who responded well to the new drug therapy no longer had the need for transfusions.
New Jersey-based oncologist and hematologist Kenneth D. Nahum, MD, treats patients with blood disorders and cancers at Regional Cancer Care Associates (RCCA). With more than 30 years of medical and clinical research experience, Dr. Kenneth D. Nahum has treated many instances of breast cancer.A recent study published in the journal of the North American Menopause Society (NAMS), revealed a link between breast cancer and vasomotor symptoms (VMS). Researchers looked at more than 25,000 women over the course of nearly 18 years. In this period, 1,399 cases of new breast cancer were diagnosed among participants. Many of the women with breast cancer had experienced persistent VMS symptoms, such as night sweats and hot flashes, that lasted for at least 10 years. Breast cancer rates were lower among women who had not experienced persistent VMS.Researchers also looked at the survival rates of women with and without persistent VMS after they were diagnosed with breast cancer. While a small difference was seen, it was not statistically significant, which suggests that persistent VMS did not affect survival rates of women with breast cancer.
Dr. Kenneth D. Nahum, an experienced clinical researcher, has served as an investigator in more than 70 drug studies over the course of 20 years. In addition, Kenneth D. Nahum, MD, serves as an oncologist (a doctor who specializes in the diagnosis and treatment of cancer) and a hematologist (a doctor who specializes in diseases related to blood).Hemophilia is an inherited condition in which the blood lacks the protein it needs to properly clot. Hemophilia is usually seen as one of two types: A or B.Hemophilia A, which accounts for roughly 80 percent of all hemophilia cases, is caused by defective or missing Factor VIII, an essential blood-clotting protein. People with defective or missing Factor VIII develop mild, moderate, or severe hemophilia A. In most situations, hemophilia A is inherited on the X chromosome. However, the condition may develop because of a spontaneous genetic mutation, which accounts for roughly a third of all hemophilia A cases.Meanwhile, hemophilia B is caused by a deficiency in Factor IX. In most ways, hemophilia B functions the same as hemophilia A. B is inherited on the X chromosome, but it can develop from a spontaneous mutation. Despite these similarities, the chance of developing hemophilia B is about four times lower than the chance of developing hemophilia A.
